Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Launched by MASONIC CANCER CENTER, UNIVERSITY OF MINNESOTA · Aug 14, 2012
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment approach for patients who need a second or greater stem cell transplant after not getting good results from their first transplant. The trial uses a method called reduced intensity conditioning (RIC), which involves giving patients a lower dose of chemotherapy and radiation to help their body accept the new stem cells. This treatment is aimed at people with blood disorders, immune system problems, or other conditions that require another transplant due to issues with their previous donor cells not working well enough.
To be eligible for this trial, participants should be between 0 to 55 years old and have a medical need for a second transplant because their first one didn't provide enough donor cells. They must also have a suitable donor, which could be a family member or an unrelated person. It's important to note that individuals with certain health conditions, like active infections or HIV, cannot participate. Those who join the trial can expect to receive careful monitoring and support throughout the process to help ensure their safety and the best possible outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of any disease for which a second or greater hematopoietic stem cell transplant is needed due to insufficient donor chimerism following hematopoietic recovery after previous HSCT. Determination of "insufficiency of donor chimerism" will be made by the treating transplant physician. Occasionally donor derived engraftment may be present, but sustained aplasia or failed recovery of sufficient hematopoiesis requires administration of a second graft. This intervention may be used for both situations.
- • Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program
- • Transplantation using sufficiently matched related donors (such as matched siblings) or unrelated donors will be considered. Both granulocyte-colony stimulating factor (GCSF) stimulated peripheral blood grafts and bone marrow grafts will be considered, although bone marrow will be the priority.
- • Cord blood grafts, both related and unrelated, are also eligible. As this protocol will use a reduced intensity regimen, this protocol will use the current recommendations of the University of Minnesota for choosing cord blood grafts. If a single cord blood unit cell dose is insufficient, double cord transplantation should be considered if sufficiently matched cord blood units are available. The priority of choosing cord blood donors is based on the current institutional recommendations.
- • Exclusion of Metabolic Disorder or other Inherited Disorder Carrier Status from related donor and unrelated cord blood grafts as appropriate for primary disease.
- • At the discretion of the treating transplant physician, an allograft from the previous donor may be used, if available.
- • Age, Performance Status, Consent
- • Age: 0 to 55 years
- • Consent: voluntary written consent (adult or parental/guardian)
- Exclusion Criteria:
- • Previous irradiation that precludes the safe administration of an additional dose of 200 cGy of total body irradiation (TBI). Radiation Oncology will evaluate all patients who have had previous radiation therapy or TBI for approval to receive an additional 200 cGy of TBI
- • Pregnant or breastfeeding
- • Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
- • HIV positive
- • While it would be advantageous to begin therapy on this second transplant regimen \> 6 months following a prior myeloablative regimen or \>2 months after a reduced intensity regimen, it is recognized that there are circumstances where this may not be practical.
About Masonic Cancer Center, University Of Minnesota
The Masonic Cancer Center at the University of Minnesota is a leading institution dedicated to cancer research, treatment, and prevention. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates innovative research with clinical practice to enhance patient care and advance medical knowledge. The center fosters collaboration among scientists, clinicians, and educators, focusing on multidisciplinary approaches to tackle the complexities of cancer. Through its commitment to cutting-edge clinical trials, the Masonic Cancer Center aims to translate scientific discoveries into effective therapies, ultimately improving outcomes for cancer patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Troy Lund, M.D., Ph.D.
Principal Investigator
Masonic Cancer Center, University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials